Mologen (MGN)

Business description

Mologen is a German biotech company developing cancer immunotherapies. The lead product is lefitolimod (MGN1703) for metastatic colorectal cancer maintenance, SCLC and HIV. Development of MGN1601, a therapeutic renal cell vaccine, would be reinitiated on successful out-licensing of lefitolimod.

Pivotal cancer immunotherapy player

QuickView | Pharmaceutical & healthcare | 09/11/2015

Mologen is developing cancer immunotherapies for the post-chemo maintenance setting. Lead product, MGN1703, is in three clinical trials for different indications. Following the €28.3m (gross) proceeds from the rights issue in April 2015, Mologen should have sufficient funds to reach full recruitment of IMPALA (Phase III in colorectal cancer) and top-line data from IMPULSE (Phase II in lung cancer); the latter could positively affect partnering or financing options for MGN1703. We value Mologen at €384m.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.€79.3m
Last close€2.135
High / Low (52 weeks)€4.5 / €1.9
Stock market listingDE
Forecast net cash (€m)0.2
Forecast gearing ratio (%)N/A
SectorPharmaceutical & healthcare

Price performance

Relative *(5)(3.5)(22.8)

* % Relative to local index

Company news

Mologen AG

Mon, 11 Dec 2017 11:21:18 GMT

Mologen AG

Tue, 10 Jan 2017 16:50:35 GMT

Mologen AG

Mon, 23 Jan 2017 08:37:30 GMT

Mologen AG

Mon, 27 Feb 2017 09:00:00 GMT

Mologen AG

Tue, 28 Jun 2016 06:22:30 GMT